Glenmark Pharmaceuticals Q4 Results: Net dips 26% to Rs 173

Consolidated revenues of the drug firm, however, rose to Rs 3,019 crore in the quarter under review as compared to Rs 2,860 crore in the year-ago period, recording an increase of 6 per cent year-on-year.

Related Keywords

Mumbai , Maharashtra , India , Glenn Saldanha , Glenmark Lifesciences , Glenmark Pharmaceuticals , Glenmark Pharmaceuticals On , Pharmaceuticals Chairman , Managing Director Glenn Saldanha , Glenmark Pharmaceuticals News , Lenmark Pharmaceuticals Q4 Results , Lenmark Pharmaceuticals Q4 Earnings ,